| | | | | | | | | | |
|
| |
|
| Dockets
Entered On January 30, 2004
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1977P-0353
|
| HAIR DYE PROD CONTAINING 4-DIAMINOANISOLE OR 4-DIAMIN-SUL
|
|
|
|
|
| 1995S-0316
|
| 75-Day Premarket Notifications for New Dietary Ingredients
|
|
|
|
|
| 2003D-0478
|
| Guidance on Marketed Unapproved Drugs Compliance Policy Guide
|
|
|
|
|
| 2003D-0493
|
| Guidance on Powder Blends and Finished Dosage Units -- Stratified In-Process Dosage Unit Sampling and Assessmen
|
|
|
|
|
| 2003D-0497
|
| Guidance for Industry on Pharmacogenomic Data Submissions
|
|
|
|
|
| 2003N-0338
|
| Obesity
|
|
|
|
|
| 2003N-0529
|
| Amending the MedWatch Forms to Collect Postmarketing Adverse Event Data Relating to Race and Ethnicity
|
|
|
|
|
| 2003P-0387
|
| Request that the Commissioner of Food and Drug take action described methodology for oral levothyroxine sodium drug products
|
|
|
|
|
| 2003P-0464
|
| ANDA for Clonazepam Oral Solution
|
|
|
|
|
| 2003P-0544
|
| Modify existing food additive regulation with respect to the irradiation of ground beef byproducts
|
|
| |
|
| 1977P-0353
|
| HAIR DYE PROD CONTAINING 4-DIAMINOANISOLE OR 4-DIAMIN-SUL
|
|
|
|
|
| BKG 2
|
| Background Material
|
| Vol #:
|
| 17
|
|
|
|
|
| 1995S-0316
|
| 75-Day Premarket Notifications for New Dietary Ingredients
|
|
|
|
|
| RPT
168
|
| PanVital, Inc
|
| Vol #:
|
| 121
|
|
|
|
|
| RPT
169
|
| Humet
|
| Vol #:
|
| 122
|
|
|
|
|
| 2003D-0478
|
| Guidance on Marketed Unapproved Drugs Compliance Policy Guide
|
|
|
| C
65
|
| National Assn of Chain Drug Stores (NACDS)
|
| Vol #:
|
| 5
|
|
|
|
|
| 2003D-0493
|
| Guidance on Powder Blends and Finished Dosage Units -- Stratified In-Process Dosage Unit Sampling and Assessmen
|
|
|
|
|
| EMC
3
|
| Facility Automation Management Engineering Systems
|
| Vol #:
|
| 1
|
|
|
|
|
| 2003D-0497
|
| Guidance for Industry on Pharmacogenomic Data Submissions
|
|
|
|
|
| C
6
|
| Global Genomic
|
| Vol #:
|
| 1
|
|
|
|
|
| C
7
|
| Expression Analysis
|
| Vol #:
|
| 1
|
|
|
|
|
| C
8
|
| Genaissance Pharmaceuticals
|
| Vol #:
|
| 1
|
|
|
|
|
| C
9
|
| AstraZeneca
|
| Vol #:
|
| 1
|
|
|
|
|
| 2003N-0338
|
| Obesity
|
|
|
|
|
| TR
4
Part 2,
3, 4
|
| Esploring the Link Between Weight Management and Food Labels and Packaging 11/20/2003
|
| Vol #:
|
| 11
|
|
|
|
|
| 2003N-0529
|
| Amending the MedWatch Forms to Collect Postmarketing Adverse Event Data Relating to Race and Ethnicity
|
|
|
|
|
| C
2
|
| Wyeth Research (Wyeth)
|
| Vol #:
|
| 1
|
|
|
|
|
| 2003P-0387
|
| Request that the Commissioner of Food and Drug take action described methodology for oral levothyroxine sodium drug products
|
|
|
|
|
| SUP
2
|
| American Thyroid Assn
|
| Vol #:
|
| 1
|
|
|
|
|
| 2003P-0464
|
| ANDA for Clonazepam Oral Solution
|
|
